MW and MR are employees of PTC Therapeutics. In connection with such employment, they receive salary, benefits and stock-based compensation. MI is an employee of Regeneron. In connection with such employment, he receives salary, benefits, and stock based compensation. Further declarations are outlined below: Consulting or Advisory Role: Daiichi Sankyo, Xencor, Apexigen, Epizyme, Caris Life Sciences Research Funding: Apexigen Inst, Mirati Therapeutics Inst, PTC Therapeutics Inst, Intensity Inst, Boehringer Ingelheim Inst, Bioatla Inst, Merck Inst, Astellas Pharma Inst, AstraZeneca Inst For BT, his declarations are outlined below: Consulting: Cytokinetics Inc Consulting/Advisor 2020 exp. 7/23 Bayer Consulting/Advisor 2021 Deciphera Pharm, Extended the consulting relationship 9/2022. Daiichi Sankyo Inc. Consulting 2021, 2022 EcoR1 Consulting 9/2022 Advenchen Consulting Putnam Consulting 2023 Salarius Pharm, Inc., Consulting 2023 Boxer Capital LLC Consulting 2023 Acuta Capital, LLC Consulting 12/2022 5 years Participation on a Data Safety Monitoring Board or Advisory Board Apexigen Inc Advisory Board Meeting 2022 Daiichi Sankyo Advisory Board Meeting 2021, CTOS 2022 Bayer US Medical Affairs Oncology Virtual Advisory Board Meeting 11/30/21 2022 PTC Therapuetics Advisory Board Meeting 2022 Aadi Biosciences CTOS advisory board, PRECISION 1: Exploring Best Practices for a Tumor Agnostic Study in an Organ-specific World 11/22 Boehringer Ingelheim Advisory Board Meeting ASCO 2022 Agenus Mini Sarcoma Ad Board 11.17.2022 CTOS 2022 exp 1 year Regeneron Pharmaceuticals Epithelioid Sarcoma Advisory Board - 11/11/2022-CTOS Advenchen 2022 EcoR1 Capital, LLC, EcoR1 CTOS Adboard 2022- not paid Curis VISTA AdBoard 8/2022 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Polaris Board Member- nonpaid Patents planned, issued or pending *Patent on the use of ME1 as biomarker *Patent on ALEXT3102 Support for attending meetings and/or travel Adaptimmune Flight paid for to present abstract 2/2023 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Iterion Therapeutics, Inc. 45 minute telephone interview about an early stage compound, tegavivant, being explored for the treatment of osteosarcoma. 10/24/2022 Total Health Conference 2023 West Oncology talk-Memphis.